Old drugs, new hope? early trial combines metformin, digoxin, and simvastatin for advanced cancers

NCT ID NCT03889795

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether a combination of three widely used drugs—metformin (for diabetes), digoxin (for heart conditions), and simvastatin (for cholesterol)—can be safely given to people with advanced pancreatic cancer or other solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and watch for side effects. Only 15 participants are enrolled, so this is a first step to see if further study is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Metformin, digoxin, and simvastatin (oral pills)

What this could lead to

If it works, this could point toward a new, low-cost combination approach for advanced cancers that have stopped responding to standard treatments.

What could go wrong

This is a very early (Phase 1) trial with only 15 people, so it is mainly checking safety and dosing. It is not designed to prove the drugs shrink tumors or extend life, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Toledo, Eleanor N. Dana Cancer Center

    Toledo, Ohio, 43614, United States